Androgen deprivation of prostate cancer: Leading to a therapeutic dead end

Androgen Deprivation for Prostate Cancer

The beneficial effects of androgen deprivation on prostate cancer have been known for more than a half century, based on work demonstrating the androgen dependency of prostate tumor cells. Androgen deprivation therapy (ADT), initially in the form of bilateral orchiectomy, has accordingly long been a mainstay for the palliation of metastatic prostate cancer. For most of its history, concerns abo...

Androgen Deprivation Therapy for Prostate Cancer

Androgen Deprivation Therapy for Prostate Cancer

AN D R O G E N D E P R I V A T I O N t h e r a p y ( A D T ; h e r e i n defined as medical or surgical castration) is the cornerstone treatment of advanced prostate cancer. In 1941, Huggins and Hodges first noted the beneficial effects of castration and injection of estrogens in patients with metastatic prostate cancer. The biological basis of the effect of ADT, the almost ubiquitous expressio...

Controversies surrounding androgen deprivation for prostate cancer.

BACKGROUND Management of metastatic prostate cancer continues to evolve. The widespread use of the prostate-specific antigen (PSA) assay has led to earlier diagnosis and earlier detection of recurrent disease. Debates continue regarding the proper use and timing of endocrine therapy with orchiectomy, estrogen agonists, luteinizing hormone-releasing hormone (LHRH) analogs, LHRH antagonists, and ...

Intermittent androgen deprivation in advanced prostate cancer.

Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of ...